Unidad de Revisiones Sistemáticas y Meta-análisis, Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru.
Facultad de Medicina de San Fernando, Universidad Nacional Mayor de San Marcos, Lima, Peru.
Am J Cardiol. 2023 Sep 15;203:98-104. doi: 10.1016/j.amjcard.2023.07.020. Epub 2023 Jul 22.
This study aimed to assess the association between frailty and clinical outcomes in patients with atrial fibrillation (AF) who undergo catheter ablation. We conducted a retrospective cohort study using the National Inpatient Sample database from 2017 to 2019. Adult patients hospitalized with a primary diagnosis of AF who underwent catheter ablation were included. Frailty was assessed using the Hospital Frailty Risk Score. The primary outcome was the presence of any complication (vascular, cardiac, respiratory, neurologic, or infectious), and secondary outcomes were in-hospital mortality, length of hospital stay, and hospital charges. A total of 21,075 weighted hospitalizations were included, and 14% were classified as intermediate or great risk of frailty. Patients with intermediate (adjusted relative risk 2.86, 95% confidence interval 2.24 to 3.67) and great (adjusted relative risk 6.68, 95% confidence interval 3.77 to 11.84) risk of frailty were associated with a greater risk of any complication than that of the group at less risk. The in-hospital mortality rate was significantly higher among patients at intermediate risk than among those at less risk of frailty (2.6% vs 0.1%, p <0.001). Patients with great and intermediate risk had significantly longer hospital stays than did the group with less risk (median 14 vs 5 vs 2 days, p <0.001), in addition to greater total charges (median $189,072 vs $161,598 vs $130,672, p <0.001), respectively. In conclusion, frailty was associated with a greater risk of poor short-term outcomes in patients with AF who underwent catheter ablation. The Hospital Frailty Risk Score is a useful tool for identifying patients at increased risk of adverse events and could aid in preoperative optimization and postoperative management.
本研究旨在评估衰弱与接受导管消融治疗的心房颤动(AF)患者临床结局之间的关联。我们使用 2017 年至 2019 年期间国家住院患者样本数据库进行了回顾性队列研究。纳入因原发性 AF 住院且接受导管消融治疗的成年患者。使用医院衰弱风险评分(Hospital Frailty Risk Score)评估衰弱。主要结局为任何并发症(血管、心脏、呼吸、神经或感染)的发生情况,次要结局为院内死亡率、住院时间和住院费用。共纳入 21075 例加权住院患者,其中 14%被归类为衰弱中度或高度风险。与低风险组相比,衰弱中度(调整后的相对风险 2.86,95%置信区间 2.24 至 3.67)和高度(调整后的相对风险 6.68,95%置信区间 3.77 至 11.84)风险的患者发生任何并发症的风险更高。与低风险组相比,中度风险组的院内死亡率显著更高(2.6% vs 0.1%,p<0.001)。与低风险组相比,衰弱高度和中度风险组的住院时间明显更长(中位数分别为 14 天、5 天和 2 天,p<0.001),总费用也更高(中位数分别为 189072 美元、161598 美元和 130672 美元,p<0.001)。总之,在接受导管消融治疗的 AF 患者中,衰弱与短期预后不良风险增加相关。医院衰弱风险评分是识别高风险不良事件患者的有用工具,有助于术前优化和术后管理。